This is a tradename for trastizumab, one of the MONOCLONAL ANTIBODY DRUGS used in treating early stage breast cancer in women with the HER2 positive type of the disease – about one in five of all those diagnosed. It is given, generally for one year, after other treatments such as chemotherapy, radiotherapy and/or surgery. It cannot be given to those with heart disease.